Nanjing Leads Biolabs Reports 8.7-Month Median Survival With LBL-024 in Late-Line EP-NEC Trial

• Nanjing Leads Biolabs presented updated LBL-024 clinical and translational results at the 2026 European Society for Medical Oncology annual meeting.
• In previously treated extrapulmonary neuroendocrine carcinoma, monotherapy showed durable responses; first-line treatment with chemotherapy showed survival benefits against historical benchmarks.
• First-line treatment with chemotherapy showed antitumor activity in advanced biliary tract cancer, including patients with PD-L1-negative tumors.
• No new safety signals emerged across the three clinical studies.
• China's regulator accepted LBL-024's marketing application in August 2026 following its inclusion in priority review in July.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261026-12383131), on October 26, 2026, and is solely responsible for the information contained therein.